AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03600311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Energy Balance
Description: Participants will consume 40 kcal/kg FFM/day.
Study NCT03600311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Post-Exercise Carbohydrate
Description: Participants will ingest 30 g of carbohydrate following exercise.
Study NCT04112563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exploration in white light (WLI)
Description: Exploration of the right colon done in white light (WLI)
Study NCT04112563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exploration in LCI
Description: Exploration of the right colon in linked color imaging (LCI)
Study NCT03397147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Coach Jr.
Description: A brief sleep education program for parents of school-aged children with type 1 diabetes, with a focus on resolving sleep disturbances with parent education and positive bedtime routines.
Study NCT03600311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Post-Exercise Carbohydrate
Description: Participants will ingest 30 g of carbohydrate following exercise.
Study NCT01323244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
Study NCT03249805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steenbeek Foot Abduction Brace (SFAB)
Description: The FAB will be equipped with discretely hidden sensors; subjects and their families will not be aware of the actual function of the sensor in order to avoid increased compliance due to the sensor. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
Study NCT03249805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiracleFeet Foot Abduction Brace (mFAB)
Description: Sensors in the mFAB will measure whether the shoe is on, the foot is in contact with the sole of the shoe and the shoes are clipped into the bar. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
Study NCT05840536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.
Study NCT02870530 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Anastomosis Sleeve Jejunal (SAS-J) Bypass
Description: Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A treatment for Morbid
Study NCT02635399 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PPPD (pylorus-preserving pancreaticoduodenectomy)
Description: pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
Study NCT02228850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04578535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants received a SC infusion of HYQVIA 0.1 g/kg (1/4 of TDL) on Day 1 and 8, 0.2 g/kg (1/2 of TDL) on Day 15, 0.3 g/kg (3/4 of TDL) on Day 29 followed by 0.4 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
Study NCT04578535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants received a SC infusion of HYQVIA 0.25 g/kg (1/4 of TDL) on Day 1 and 8, 0.5 g/kg (1/2 of TDL) on Day 15, 0.75 g/kg (3/4 of TDL) on Day 29 followed by 1.0 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
Study NCT04578535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants received a SC infusion of HYQVIA 0.2 g/kg (1/2 of TDL) on Day 1 and 15, followed by 0.4 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
Study NCT04578535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants received a SC infusion of HYQVIA 0.5 g/kg (1/2 of TDL) on Day 1 and 15, followed by 1.0 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
Study NCT04578535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants received a SC infusion of HYQVIA 0.4 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
Study NCT04578535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants received a SC infusion of HYQVIA 1.0 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
Study NCT03556020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemziviptadil (PB1046)
Description: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
Study NCT03317119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03317119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT03317119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study NCT01699568 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: Each week since the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequence analysis, using the smartpeg number 21
Study NCT01699568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Each week since the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequence analysis, using the smartpeg number 21
Study NCT02402413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The patients will be subjected to ultrasound bi-dimensional or three-dimensional. Will Be calculated the ratio stroma/volume with both methods
Study NCT02402413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Determination of concentrations of androgens
Description: Determination of concentrations of serum levels of circulating androgens
Study NCT02402413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three dimensional ultrasound probe
Description: Capture of ovarian three dimensional volumes
Study NCT03341455 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Capacity building to support families affected by IPV & substance misuse
Description: Training targeted groups (mothers, fathers, preschool teachers, community officers managing preschools) separately with the aim to identify and support high-risk families early enough to arrest the cycle of violence that results in children themselves becoming victims and perpetrators of such violence.
Study NCT02379468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pedyphar Ointment
Study NCT02379468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panthenol
Description: Ointment
Study NCT03087292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training with vascular occlusion
Description: Patients will perform unilateral leg extension resistance training with vascular occlusion 2 times per week for a period of 8 weeks. Each training session will consist of 3 sets of 15 repetitions at the intensity of 30% 1 RM with 30 s of rest period between sets.
Study NCT04416906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy
Description: Once daily fixed dose combination regimen of Biktarvy will be evaluated as a rapid treatment strategy in newly HIV diagnosed patients HIV diagnosed patients that come for the first time to the Hospital Clínic HIV Unit
Study NCT02317978 — intervention group
Intervention type: PROCEDURE
Intervention: ICSI
Description: records of women who had ICSI will be reviewed and analysed for determining FSI
Study NCT01829022 — intervention group
Intervention type: PROCEDURE
Intervention: E-NOTES
Description: Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
Study NCT01243827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP \<140/90 mmHg.
Study NCT01243827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bisoprolol
Description: bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP \<140/90 mmHg.
Study NCT03394352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity on Board
Description: During the collection phase, the study team will collect information on glucose values, activity measures and insulin settings. This information will be used to determine the meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the data collection phase and study admission.
Study NCT03394352 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Diabetes Care
Description: Subjects will perform their usual diabetes care including basal rate, meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the study admission.
Study NCT02315482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pneumoperitoneum insufflation and steep trendelenburg
Description: the sequence of pneumoperitoneum insufflation and steep trendelenburg positioning is randomized
Study NCT04533867 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Sleeve gastrectomy, also called a vertical sleeve gastrectomy, is a surgical weight-loss procedure. This procedure is typically performed laparoscopically, which involves inserting small instruments through multiple small incisions in the upper abdomen. During sleeve gastrectomy, about 80 percent of the stomach is removed, leaving a tube-shaped stomach about the size and shape
Study NCT04533867 — intervention group
Intervention type: DRUG
Intervention: Palonosetron 1mcg/kg
Description: Injectable Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution and injected intravenously at the end of the bariatric surgery.
Study NCT01885312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Tailored Intervention
Description: Adaptive
Study NCT01885312 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consequence-based Intervention
Description: Loss Framed
Study NCT04533867 — intervention group
Intervention type: DRUG
Intervention: Ondansetron 1 mg/kg, max dose 8 mg
Description: Injectable ondansetron 0.1 mg/kg, maximum of 8 mg was injected intravenously at the end of the bariatric surgery.
Study NCT03088813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection
Description: IV
Study NCT03600311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Participants will be supplied Calcium and Vitamin D supplements throughout the study period matched to the CON condition.
Study NCT03600311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D
Description: Participants will be supplied Calcium and Vitamin D supplements throughout the study period matched to the CON condition.
Study NCT03600311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Participants will be supplied Calcium and Vitamin D supplements throughout the study period matched to the CON condition.
Study NCT05170516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4 °C colled saline irrigation
Description: In Experimental Group A , 4 °C colled saline irrigation was used during impacted third molar surgery
Study NCT05170516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 10 °C cooled saline irrigation
Description: Experimental Group B, 10°C colled saline irrigation was used during impacted third molar surgery.
Study NCT01885312 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored, not adaptive, based Intervention
Description: Baseline tailored not adaptive
Study NCT01885312 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment only
Description: EMA only
Study NCT02724904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Description: Reduced intensity allogeneic stem cell transplantation from a fully matched related or unrelated donor
Study NCT05170516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Room temperature saline irrigation
Description: In Control Group A and B, salin irrigation at room temperature was used during impacted third molar surgery.
Study NCT00498784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirena
Description: Mirena 52mg during 1 year
Study NCT00668876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral IMPACT
Description: oral supplementation for 5 days(1 L/d )before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
Study NCT00668876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral IMPACT
Description: postoperative enteral infusion of the formula with arginine, omega-3 fatty acids, and RNA
Study NCT00668876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral nutrition
Description: Parenteral nutrition
Study NCT03575975 — intervention group
Intervention type: DEVICE
Intervention: Total Ankle Replacement Prosthesis
Description: Comparison of functional range of motion in users of Stryker Scandinavian Total Ankle Replacement (STAR) prosthesis to users of INBONE 2 Total Ankle Replacement prosthesis and to matched controls with intact ankle joints.
Study NCT03479424 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: The MYIA in-home suite of devices.
Study NCT03061617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VCV mode
Description: set fixed 6ml/kg tide volume
Study NCT03061617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCV mode
Description: adjust pressure to achieve tide volume of 6ml/kg
Study NCT03066687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Erdafitinib 9 mg (provided as one 4-mg tablet \[G-024\] and one 5-mg tablet \[G-025\]) will be administered orally on Day 1 in each Treatment Period of assigned sequence.
Study NCT02635399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPPD (pylorus-preserving pancreaticoduodenectomy) with DJ-pexy
Description: pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
Study NCT01443039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenotypical approach
Description: each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
Study NCT04416074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An online 5-week professional identity group psychotherapy
Description: This is an online 5-week group psychological intervention for the nursing students during clinical rotation practice. It aims at promoting the professional identity and career sefl-efficacy for them. There are five sessions in the intervention, and each session lasts from 60min to 90min at each week. The intervention will be delivered via an online meeting software, like Zoom. There will be 15-20 students in one meeting group.
Study NCT04416074 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Message push
Description: Controlled group will receive online messages of self-care knowledge forward by researchers once per week. The knowledge contain stress regulation, strategies for relaxation, self-protection during clinical practice.
Study NCT03328325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
Study NCT03328325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
Study NCT00186121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole (Arimidex)
Description: Anastrozole is a prescription hormonal treatment that helps fight breast cancer by lowering the amount of estrogen in the body. It is a non-steroidal aromatase inhibitor, which significantly lowers serum estradiol (estrogen) concentrations, without interfering with the formation of adrenal corticosteroids or aldosterone
Study NCT01826994 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: heart type fatty acid binding protein testing
Study NCT01916109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT01916109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01916109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Study NCT01916109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical cystectomy
Study NCT00103857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily)
Description: MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take MK0431 50 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
Study NCT00103857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0431 100 mg q.d. (q.d. = once daily)
Description: MK0431 oral tablets will be started on Day 1 as two 50 mg tablets (100 mg q.d.) (q.d. = once daily) and continued at this dose throughout the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
Study NCT00103857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (Phase A)/Metformin (Phase B)
Description: During the placebo-controlled period (Day 1 through Week 24/Phase A), metformin and MK0431 matching placebos will be dispensed as oral tablets. At the beginning of the 30-week active-controlled period (Phase B), metformin will be started as 500 mg q.d. (q.d. = once daily) and up-titrated in 500 mg weekly increments to a stable dose of 1000 mg b.i.d. Patients who complete the 54-week base study and who enter the 50-week extension study will continue to take metformin 1000 mg b.i.d. (b.i.d. = twice daily) for a total placebo/metformin treatment duration of up to 104 weeks.
Study NCT00103857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Metformin 500 mg b.i.d.
Description: Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased after 1 week to a stable dose of 500 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 500 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.